No Direct Comparison Data Between Tirzepatide and Retatrutide from TRIUMPH-5
There is currently no published head-to-head comparison data between tirzepatide and retatrutide from the TRIUMPH-5 trial or any other clinical trial in humans. The evidence provided does not contain any TRIUMPH-5 trial results, and retatrutide remains an investigational agent without direct comparative human efficacy data against tirzepatide.
What We Know About Retatrutide
The only available comparative data comes from preclinical animal studies:
In diabetic kidney disease models: Retatrutide showed superior weight reduction and renal function improvement compared to tirzepatide in db/db mice, though tirzepatide demonstrated better glycemic control 1
In MC4R-deficient obesity models: Tirzepatide achieved greater weight reduction (31.6% body weight loss) compared to retatrutide (24.1%) in knockout mice 2
These animal studies cannot be extrapolated to clinical practice and do not inform treatment decisions.
Current Clinical Evidence for Tirzepatide
For patients requiring weight loss therapy now, tirzepatide has robust head-to-head human trial data:
Tirzepatide vs Semaglutide (SURMOUNT-5)
- Weight loss: Tirzepatide 10-15 mg achieved 21.5% body weight reduction vs 14.5% with semaglutide 2.4 mg (difference of 7.1%, p<0.001) 3
- Metabolic outcomes: Greater HbA1c reduction (-0.60% vs -0.48%, p<0.001) and higher reversion to normoglycemia (89.9% vs 76.2%) in prediabetes 3
- Safety: Comparable gastrointestinal adverse events, though serious adverse events were numerically higher with tirzepatide 4
Clinical Decision-Making Framework
Choose tirzepatide over GLP-1 agonists when:
- Weight loss is the primary treatment goal in lower cardiovascular risk patients 5
- Patient has obesity with prediabetes requiring aggressive metabolic intervention 3
Exercise caution with tirzepatide:
- In moderate-to-high cardiovascular/renal risk patients, add or continue SGLT-2 inhibitors when choosing tirzepatide over GLP-1 agonists, as tirzepatide lacks proven cardiovascular and kidney outcome benefits that GLP-1 agonists possess 5
- Never combine tirzepatide with GLP-1 agonists 5
Bottom Line
Retatrutide remains investigational without published human comparative trials. Until TRIUMPH-5 or similar trials report results, prescribe tirzepatide based on its established superiority over semaglutide for weight loss 6, 3, while recognizing that GLP-1 agonists retain advantages for cardiovascular and kidney protection that should guide therapy in higher-risk populations 5.